Lexaria Bioscience (LEXX) Non-Current Debt (2011 - 2020)

Lexaria Bioscience's (LEXX) quarterly Non-Current Debt came in at $30852.0 in Q4 2020, up 0.59% quarter-over-quarter from $30670.0 in Q3 2020.

Lexaria Bioscience (LEXX) Non-Current Debt (2011 - 2020) Analysis & Trends

Lexaria Bioscience has disclosed Non-Current Debt across 2 years of filings, most recently posting $30852.0 for Q4 2020.

Non-Current Debt for Q4 2020 came in at $30852.0, changed N/A year-over-year; the trailing twelve-month figure through Nov 2020 was $30852.0 (changed N/A YoY), and the FY2020 annual result was $30670.0, changed N/A from the prior year.
Non-Current Debt came in at $30852.0 for Q4 2020 at Lexaria Bioscience, up from $30670.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $30852.0 in Q4 2020 to a low of $28756.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Lexaria Bioscience	7.17 Mn	1.65 Mn	20,000.00	-

Download Data